Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech has filed an investigational new drug application with the FDA to initiate human clinical investigation of a Curis co-developed drug candidate for the topical treatment of skin cancer.
Subscribe to our email newsletter
This drug candidate, an antagonist of the Hedgehog signaling pathway, is being developed to treat basal cell carcinoma, the most common form of all human cancers. It was discovered by Curis and is being co-developed through a collaboration between Genentech and Curis.
Numerous preclinical reports have linked abnormal activation of the Hedgehog pathway to the growth of several solid tumors, including basal cell carcinoma, pancreatic cancer, small cell lung cancer, prostate cancer, and others.
“The filing of this investigational new drug application (IND) is an important milestone for Curis,” said Daniel Passeri, president and CEO of Curis. “We believe that Genentech’s proven expertise in the development of specifically targeted cancer therapeutics will provide an effective path forward for the Hedgehog pathway antagonist drug candidates.”